Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022 08:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced six...
Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
March 10, 2021 17:12 ET
|
Nurix Therapeutics, Inc.
CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cellsPreclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1...